Biotechnology - eliglustat

Filter

Current filters:

eliglustat

Popular Filters

Genzyme's eliglustat meets endpoints in Ph III studies for Gaucher disease

18-02-2013

US biotech firm Genzyme, a subsidiary if French drug major Sanofi (Euronext: SAN) has released positive…

BiotechnologyeliglustatGenzymePharmaceuticalRare diseasesResearchSanofi

Positive Ph II results for Genzyme’s oral Gaucher drug

09-02-2012

French drug major Sanofi’s (Euronext: SAN) US subsidiary Genzyme yesterday revealed four-year follow-up…

BiotechnologyeliglustatGenzymePharmaceuticalRare diseasesResearchSanofi

Back to top